Mij

MIJ 821: Developed by Novartis for Treatment Resistant Depression - Global Emerging Insight and Market Forecast 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 11, 2021
Pharmaceutical, Health, Clinical trials, Branches of biology, Ionotropic glutamate receptors, Life sciences, Biology, NMDA receptor antagonists, GRIN2B, Major depressive disorder, Novartis, NMDA receptor, Mij, Treatment-resistant depression

MIJ 821 acts as NR2B N-Methyl D-Aspartate receptor modulators and is being developed by Novartis for Treatment Resistant Depression.

Key Points: 
  • MIJ 821 acts as NR2B N-Methyl D-Aspartate receptor modulators and is being developed by Novartis for Treatment Resistant Depression.
  • "MIJ 821 - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Treatment Resistant Depression in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
  • Other emerging products for Treatment Resistant Depression are giving market competition to MIJ 821 and launch of late-stage emerging therapies in the near future will significantly impact the market.

MIJ Korea Unveils First Digital Tinnitus Care Smartphone App in CES 2021

Retrieved on: 
Friday, January 15, 2021
Audiology, Auditory perception, Occupational safety and health, Health sciences, Symptoms, Tinnitus, Hallym University, Clinical medicine, Medicine, Chuncheon, Mij

CHUNCHEON, GANGWON-DO, South Korea, Jan. 15, 2021 /PRNewswire/ -- MIJ introduce a tinnitus care solution, CARE4EAR in CES 2021.

Key Points: 
  • CHUNCHEON, GANGWON-DO, South Korea, Jan. 15, 2021 /PRNewswire/ -- MIJ introduce a tinnitus care solution, CARE4EAR in CES 2021.
  • MIJ has developed a tinnitus care solutions system since 2018 to solve these problems and finally released the tinnitus care app 'CARE4EAR' that makes tinnitus care easy to use anytime and anywhere.
  • MIJ proved the effectiveness of its tinnitus care solution through clinical trials and researches, conducted jointly with Hallym University, Korea in 2019.
  • In 2020 CARE4EAR continued further research in context with care app and a significant positive effect on tinnitus care has been demonstrated.